Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non-interventional study

Johannes Oldenburg, Huyen Tran, Flora Peyvandi, Ramiro Núñez, Peter Trask, Sammy Chebon, Johnny N. Mahlangu, Michaela Lehle, Victor Jiménez-Yuste, Sylvia von Mackensen

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


Introduction: Real-world data on health-related outcomes in persons with haemophilia A (PwHA) can provide useful information for improving patient care. The global, non-interventional study (NIS; NCT02476942) prospectively collected high-quality data in PwHA, including those without factor VIII (FVIII) inhibitors treated according to local routine clinical practice. Aim: To report health-related quality of life (HRQoL) and health status of adult/adolescent PwHA without FVIII inhibitors. Methods: Participants were PwHA without FVIII inhibitors age ≥12 years; they remained on existing episodic treatment or prophylaxis. HRQoL was assessed by Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) or Haemophilia-Specific Quality of Life Assessment for Children and Adolescents Short Form (Haemo-QoL-SF II). Health status was assessed through EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) index utility score and visual analogue scale (EQ-VAS). Results: Ninety-four participants enrolled; median age was 34.0 years (range 12–76). Forty-five received episodic treatment and 49 received prophylaxis for a median time of 27.7 weeks and 30.4 weeks, respectively. Mean (standard deviation) baseline Haem-A-QoL total scores were 40.1 (17.0) for the episodic group and 26.6 (14.6) for the prophylaxis group, indicating impairments in HRQoL, which remained consistent over time. Mean EQ-5D-5L IUS scores were similar between treatment regimens (0.8 episodic; 0.9 prophylaxis) and consistent over time. The mean EQ-VAS scores were similar between treatment regimens, and lower on days when bleeding occurred (79.0 vs 85.0 for episodic treatment; 77.0 vs 82.0 for prophylaxis, respectively). Conclusions: Adult and adolescent PwHA without FVIII inhibitors had HRQoL impairments regardless of whether they were treated with episodic or prophylactic standard care with FVIII.

Original languageEnglish
Pages (from-to)398-407
Number of pages10
Issue number3
Publication statusPublished - May 2021
Externally publishedYes


  • factor VIII
  • haemophilia A
  • health-related quality of life
  • inhibitors
  • non-interventional study
  • real-world data

Cite this